Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

I'm unable to read the mans mind as to why he appears to have only been speaking about the trial being run in the US in the Jan 29, 21 PR. Was it due to knowing the other was already in progress? Who knows? Not I...

As per the Nov 16, 2020 PR he clearly had already applied for a trial outside of the US.

http://www.ipharminc.com/press-release/2020/11/15/innovation-pharmaceuticals-announces-overseas-regulatory-filing-submitted-for-covid-19-clinical-study

WAKEFIELD, MA – November 16, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial of Brilacidin for COVID-19, which is on track to commence in 2020 upon gaining required approvals.

Worse yet, I can't even answer the following question definitively:
When is clinical trial considered to be started? At time listed on a clinical trials registry or at first patient ok'd for trial, or, at first patient dosing?










Message in reply to:
If the trial did indeed begin in December...

then why did LE put out a PR stating:

WAKEFIELD, MA – January 29, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company’s Phase 2 clinical trial of Brilacidin for treating COVID-19 is scheduled to begin next week.

If it began in December, why state in late January it was scheduled to begin the following week? The trial is a singular enterprise, whether or not multiple sites are involved. Even in the Nov 16th announcement the trial is referred to singularly:

...that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA. Both these submissions are part of final preparations for the Company’s multinational Phase 2 clinical trial [singular] of Brilacidin for COVID-19...